Migraine Market Report- Current and Future Players | Global Drug Forecast and Market Analysis to 2030

Migraine Market report covers vast drivers, limitations, and opportunities to give a definite picture of the market. Moreover, the Migraine Market research report provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

Get FREE PDF Sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5154430

Migraine is a complex neurological condition characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

The two clinically and commercially relevant segments considered for the classification of migraine in this report are patients with episodic migraine, who suffer up to 14 migraines per month, and patients with chronic migraine, who suffer 15 or more attacks per month.

For patients that experience four or more migraine attacks per month, physicians look to prescribe a preventive treatment. Preventive treatment is considered an additive to acute therapy and minimizes the risk of medication overuse headaches associated with Nonsteroidal anti-inflammatory drug (NSAID) and triptan treatment.

The migraine market in the 7MM was valued at $4.7B in the 2020 baseline year. RNR anticipates that over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.9%, reaching $12.0B by 2030. The major driver for this growth will be the increased prescription of calcitonin gene-related peptide (CGRP) antagonists, gepants, and monoclonal antibodies (mAbs). In addition, the launch of five new pipeline products which will have higher annual costs of therapy (ACOTs) when compared with the cost of the most commonly used migraine treatments, will drive further growth into this market. In order of entry, these products will include Axsome Therapeutics’ AXS-07, Zosano Pharma’s Qtrypta, Biohaven Pharmaceutical’s zavegepant (intranasal), Satsuma Pharmaceuticals’ STS101, and Biohaven Pharmaceutical’s zavegepant (oral).

Key Highlights-
- The prevalence of migraine is increasing in line with population growth in the 7MM.
- Oral triptans are the first-line therapy for acute migraine treatment. First-line therapies for migraine prophylaxis depend on the patients’ comorbidities and include anti-epileptic agents, antidepressants, beta blockers, and angiotensin receptor blockers.
- The greatest unmet need in the migraine market is access to effective and tolerable prophylactic treatments, in addition to the need for more efficacious acute therapy options.
- The migraine pipeline is dominated by reformulations of mature products with novel delivery devices that provide preferable route of administration to patients.
- The migraine market will exhibit significant growth between 2020 and 2030, driven by the increased prescription of anti-CGRP mAbs and small molecule CGRP antagonists, gepants.

Key Questions Answered-
- What are the key migraine treatments available in 2020?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall migraine market in the 7MM?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope of this Report-
- Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic migraine and chronic migraine) forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy this Report-
Migraine Market report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Discount on Purchase this Report @ https://www.reportsnreports.com/purchase.aspx?name=5154430

Table of Contents
1 Migraine: Executive Summary
1.1 Migraine Therapeutics Market will grow to $12.0B
1.2 Key Players Will Maintain Their Competitive Position
1.3 Access to Effective and Tolerable Prophylactic Treatments and Additional Acute Therapy Options Remain Unmet Needs
1.4 The Gepants Are the Most Promising New Entrants to the Migraine Market
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
3.2.1 Premonitory Phase
3.2.2 Aura Phase
3.2.3 Headache Phase
3.2.4 Resolution Phase
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 7MM Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine
4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency
4.4.5 12-Month Total Prevalent Cases of Migraine by Type
4.4.6 12-Month Diagnosed Prevalent Cases of Migraine
4.5 Epidemiological Forecast for Migraine (2020-2030)
4.5.1 12-Month Total Prevalent Cases of Migraine
4.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine
4.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine
4.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic
4.5.5 12-Month Total Prevalent Cases of Migraine by Type
4.5.6 12-Month Diagnosed Prevalent Cases of Migraine
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Episodic Migraine
5.1.2 Chronic Migraine
5.2 Additional KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders
7.3 Limited Acute Therapies for Patients Unresponsive to Triptan Medication
7.4 Access to Effective and Tolerable Prophylactic Treatments
7.5 Physician Education for Diagnosis
7.6 Raise Awareness of the Disease in the General Population
8 R&D Strategies
8.1 Overview
8.1.1 Gepants for Dual-Acting Acute and Preventive Indications
8.1.2 Preventive Drugs with Long Duration of Action
8.1.3 Improving Efficacy of Marketed Migraine Drugs
8.1.4 Novel MOAs
8.2 Clinical Trials Design
8.2.1 Study Design
8.2.2 Endpoints for Migraine Clinical Trials
8.2.3 Patient Recruitment
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
10.2.1 Acute Treatment for Migraine
10.2.2 Preventive Treatment for Migraine
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs Interviewed for This Report
13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Managing Analyst
13.6.3 Therapy Area Director
13.6.4 Epidemiologist
13.6.5 Managing Epidemiologist
13.6.6 Global Director of Therapy Analysis and Epidemiology
13.6.7 Global Head and EVP of Healthcare Operations and Strategy
Contact Us

+ 1 888 391 5441
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.